(Q39549271)

13 September 2017

title

Alternol exerts prostate-selective antitumor effects through modulations of the AMPK signaling pathway (English)

1 reference

13 September 2017

Eddie D Yeung

1

1 reference

13 September 2017

Alex Morrison

2

1 reference

13 September 2017

Daniel Plumeri

3

1 reference

13 September 2017

Jingying Wang

4

1 reference

13 September 2017

Chao Tong

5

1 reference

13 September 2017

Xiaoyan Yan

6

1 reference

13 September 2017

Ji Li

7

1 reference

13 September 2017

publication date

2 May 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

72

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

165-172

1 reference

13 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

The changing face of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Role of targeted therapy in the treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Mitochondrial DNA determines androgen dependence in prostate cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

A newly synthetic chromium complex-chromium (D-phenylalanine)3 activates AMP-activated protein kinase and stimulates glucose transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

AMPK, the metabolic syndrome and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

AMP-activated protein kinase promotes human prostate cancer cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Redox-directed cancer therapeutics: molecular mechanisms and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Mechanism of action of taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Inactivation of Bcl-2 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Autophagic cell death unraveled: Pharmacological inhibition of apoptosis and autophagy enables necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21417

Alternol inhibits proliferation and induces apoptosis in mouse lymphocyte leukemia (L1210) cells

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1007/S11010-007-9560-0

Identifiers

DOI

10.1002/PROS.21417

1 reference

13 September 2017

1 reference